Yttrium (90Y) tacatuzumab tetraxetan is an investigational humanized monoclonal antibody intended for the treatment of cancer.

[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.

This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.

You can help Wikipedia by expanding it.This nuclear medicine article is a stub.